je.st
news
Orsiro From BIOTRONIK, Industry's First Hybrid Drug-Eluting Stent, Performs As Best In Class
2013-06-05 07:26:54| drugdiscoveryonline News Articles
Primary end-point results from the BIOFLOW-II Clinical Study demonstrating the non-inferiority of the BIOTRONIK Orsiro Hybrid Drug-Eluting Stent compared to Abbott's XIENCE PRIME™
Tags: in
class
hybrid
performs
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||